Company Description
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease.
Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy.
It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance.
The company is based in Calgary, Canada.
| Country | Canada |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Allen Davidoff |
Contact Details
Address: 3710 – 33rd Street NW Calgary, AB T2L 2M1 Canada | |
| Phone | 403-455-7727 |
| Website | xortx.com |
Stock Details
| Ticker Symbol | XRTX |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001729214 |
| CUSIP Number | 98420Q207 |
| ISIN Number | CA98420Q3061 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, Chief Executive Officer, President and Director |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer |
| Dr. Michael Scott Bumby D.V.M., M.B.A. | Chief Financial Officer |
| Nick Rigopoulos | Director of Communications |
| Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations |
| Charlotte May | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 20-F | Annual and transition report of foreign private issuers |
| May 1, 2025 | NT 20-F | Notification of inability to timely file Form 20-F |
| Apr 30, 2025 | 6-K | Report of foreign issuer |
| Apr 28, 2025 | 6-K | Report of foreign issuer |
| Apr 18, 2025 | 6-K | Report of foreign issuer |
| Apr 1, 2025 | 6-K | Report of foreign issuer |
| Mar 26, 2025 | 6-K | Report of foreign issuer |
| Mar 19, 2025 | 6-K | Report of foreign issuer |
| Feb 24, 2025 | 6-K | Report of foreign issuer |
| Feb 14, 2025 | SCHEDULE 13G | Filing |